Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective
Journal
Reviews in Endocrine and Metabolic Disorders
ISSN
1389-9155
1573-2606
Date Issued
2023
Author(s)
Fabian Pitoia
Rafael Selbach Scheffel
Ines Califano
Alicia Gauna
Fernanda Vaisman
Alejandro Roman Gonzalez
Ana Oliveira Hoff
Ana Luiza Maia
Type
Resource Types::text::journal::journal article
Cite this document
Pitoia, F., Scheffel, R. S., Califano, I., Gauna, A., Tala, H., Vaisman, F., Gonzalez, A. R., Hoff, A. O., & Maia, A. L. (2024). Management of radioiodine refractory differentiated thyroid cancer: The Latin American perspective. Reviews in Endocrine and Metabolic Disorders, 25(1), 109-121. https://doi.org/10.1007/s11154-023-09818-0
Subjects
latin america
;
multikinase inhibitors
;
radioiodine refractory
;
target therapy
;
thyroid cancer
;
brazil
;
humans
;
iodine radioisotopes
;
latin america
;
protein kinase inhibitors
;
thyroid neoplasms
;
cabozantinib
;
entrectinib
;
fluorodeoxyglucose f 18
;
larotrectinib
;
lenvatinib
;
phosphatidylinositol 3 kinase
;
radioactive iodine
;
sorafenib
;
protein kinase inhibitor
;
computer assisted tomography
;
differentiated thyroid cancer
;
european medicines agency
;
high throughput sequencing
;
human
;
molecular fingerprinting
;
multidisciplinary team
;
nuclear magnetic resonance imaging
;
nuclear medicine
;
overall response rate
;
overall survival
;
pathologist
;
personalized medicine
;
progression free survival
;
response evaluation criteria in solid tumors
;
review
;
systemic therapy
;
thyroid cancer
;
thyroid papillary carcinoma
;
brazil
;
south and central america
;
thyroid tumor